Moxonidine Effects on Neuropeptide Y

Study Overview
=================
Brief Summary
-----------------
Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension

Detailed Description
-----------------
Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks

Official Title
-----------------
Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study

Conditions
-----------------
Obesity, Hypertension

Intervention / Treatment
-----------------
* Drug: Moxonidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy Exclusion Criteria: age beyond 25-75 years, not taking currently anti-hypertensive medication not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group<br>0.6 mg moxonidine daily | Drug: Moxonidine<br>* 0.6 mg moxonidine daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum Neuropeptide Y levels | ELISA | 12 weeks | 
| systolic blood pressure | mmHg | 12 weeks | 
| diastolic blood pressure | mmHg | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight | kg | 12 weeks | 
| Body Mass Index | kg/m2 | 12 weeks | 
| Total Cholesterol | mg/dl | 12 weeks | 
| HDL Cholesterol | mg/dl | 12 weeks | 
| LDL Cholesterol | mg/dl | 12 weeks | 
| Serum triglycerides | mg/dl | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, obesity, Neuropeptide Y, moxonidine